Marie Hu, MD, discusses her decision-making process when considering bispecific antibodies vs CAR T-cell therapy in patients with DLBCL.
Marie Hu, MD
Advertisement
Articles by Marie Hu, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos
2
FDA Receives BLA for Etentamig in R/R Multiple Myeloma
3
T-DXd Gains EU Approval in Residual HER2+ Early Breast Cancer
4
Basser Center for BRCA Awards 2026 Global Prize to Judy Garber
5